The Lancet, one of the leading Medical Science researchers, published in their Diabetes & Endocrinology journal on 21 March 2022 a new paper examining the post-acute risk and burden of incident diabetes in people who survived the first 30 days of SARS-CoV-2 infection. This study found that people who recovered from Covid-19 within the past year are 40% more likely to receive a new diagnosis of diabetes compared to those who weren’t infected. The increased risk translates into 1% of people who have had Covid-19 developing diabetes who otherwise wouldn’t have, the study’s author says, resulting in potentially millions of new cases worldwide.
Stanford University professor and microbiologist, Peter Jackson also suggested that the virus may cause diabetes. In a separate study published in the journal Cell Metabolism in May 2021, Peter showed that SARS-CoV-2 infects cells in the pancreas that produce insulin and may even target and destroy them.
At the same time, Paolo Fiorina, a professor of endocrinology at the University of Milan, published a study of 551 patients with no prior history of diabetes showing that 46 percent were newly hyperglycaemic. COVID-19 had completely disrupted the hormone profile of these patients—although their levels had been normal before their infection, now their glucose was dangerously high as their body had become less efficient at using insulin.
Marc Howells, CEO of Goodbody Health, noted:
“We’re starting to see a lot of increasing evidence that COVID-19 could trigger diabetes. It might take many more years to determine if COVID-19 can cause diabetes from scratch or if COVID-19 is increasing diabetes diagnoses in people pre-disposed to the chronic disease. However, all the warning signs are there. I don’t want to be alarmist but the real concern is even those who don’t have diabetes in the months after their COVID-19 infection, may still develop it in the future.
We know diabetes has serious repercussions for one’s health so it’s going to be more important than ever that people start taking a regular blood test to MOT their blood and monitor their health. Goodbody Health is already proving to be a beneficiary of this trend. We’re seeing an increasing demand for our Heart Health diabetes and cholesterol tests that offer results in minutes as well as our comprehensive Well Man and Well Women tests in our Goodbody Clinics and partner sites as more people are becoming acutely aware that prevention is better than cure.”
Know More. Live Better. Goodbody Health provides healthcare testing services in the local community.
The Goodbody Health Group Inc. is listed on the Canadian Securities Exchange (CSE), the Aquis Stock Exchange – Growth Market (AQSE) Apex segment, OTC Pink, and Frankfurt Stock Exchange (FSE), providing current and prospective shareholders with multiple platforms in which to buy and sell Goodbody Health Group Inc. stock under the EPIC codes: CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: GDBYF).